New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLiraglutide vs Adamax

Liraglutide vs Adamax

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide
Cognitive Enhancement
Adamax
Summary
Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
Half-Life
~13 hours (once-daily dosing)
Estimated 1-3 hours (short; peptide degradation)
Admin Route
SubQ
Subcutaneous, Intranasal (research)
Research
Typical Dose
Start 0.6 mg, titrate to 3 mg
200-400 mcg per dose
Frequency
Once daily
Once daily or every other day
Key Benefits
  • Promotes weight loss (5–10% average)
  • Reduces appetite and caloric intake
  • Improves blood glucose control (HbA1c reduction)
  • Reduces cardiovascular events in T2DM (LEADER trial)
  • Slows gastric emptying
  • FDA-approved for T2DM and chronic weight management
  • Cardioprotective effects shown in clinical trials
  • May improve fatty liver (NAFLD/NASH)
  • Proposed enhancement of learning and memory consolidation
  • Neuroprotective via BDNF-TrkB pathway support
  • May improve mood and resilience to stress
  • Potential support for neurogenesis
  • Cognitive clarity and focus enhancement (reported anecdotally)
  • Explored for neurodegeneration and age-related cognitive decline
Side Effects
  • Nausea (very common, especially initially)
  • Vomiting
  • Diarrhea or constipation
  • Decreased appetite
  • +5 more
  • Limited human safety data; largely anecdotal reports
  • Possible headache or mild overstimulation
  • Sleep disruption with late-day dosing
  • Unknown long-term safety profile
Stacks With